Upgrades Hold Buy X

ALXO ALX Oncology

Jefferies

$2 $3

Downgrades Buy Hold X

ALXO ALX Oncology

Jefferies

$12 $2

Downgrades Buy Hold X

ALXO ALX Oncology

Stifel

$10 $14

Upgrades Hold Buy X

ALXO ALX Oncology

Jefferies

$8 $18

Downgrades Buy Hold X

ALXO ALX Oncology

Jefferies

$65 $25

Resumed Outperform X

ALXO ALX Oncology

Credit Suisse

$98

Resumed Outperform X

ALXO ALX Oncology

Credit Suisse

$98

Initiated Buy X

ALXO ALX Oncology

UBS

Initiated Buy X

ALXO ALX Oncology

H.C. Wainwright

$100

ALXO  ALX Oncology Holdings Inc

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.